Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04666038
Title Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With CLL or SLL
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Loxo Oncology, Inc.
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Idelalisib + Rituximab

LOXO-305

Bendamustine + Rituximab

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.